| Chronic lymphocytic leukemia (CLL) with borderline immunoglobulin heavy chain mutational status, a rare subgroup of CLL with variable disease course F Angotzi, A Cellini, V Ruocco, CA Cavarretta, I Zatta, A Serafin, S Pravato, ... Cancers 16 (6), 1095, 2024 | 2 | 2024 |
| Patients with Chronic Lymphocytic Leukemia Carrying t (14; 19) Display a Distinctive Transcriptomic Profile and Adverse Outcome, Which Might be Overcome Continuous Therapy with … A Visentin, E Gaffo, M Furstenau, JA Woyach, P Baliakas, KA Rogers, ... Blood 142 (Supplement 1), 3275-3275, 2023 | 1 | 2023 |
| Serum Soluble Interleukin-2 Receptor Levels in Hairy Cell Leukemia as a Marker of Tumor Burden with Prognostic Value and As a Tool for Disease Monitoring F Angotzi, S Zoletto, A Cellini, C Cavaretta, V Ruocco, I Zatta, L Forlani, ... Blood 142, 4414, 2023 | 1 | 2023 |
| Protein kinase CK2α is overexpressed in classical hodgkin lymphoma, regulates key signaling pathways, PD-L1 and may represent a new target for therapy E Ruggeri, F Frezzato, N Mouawad, M Pizzi, F Scarmozzino, G Capasso, ... Frontiers in Immunology 15, 1393485, 2024 | | 2024 |
| Exploring the prognostic role of complex karyotype in chronic lymphocytic leukaemia patients treated with venetoclax‐based regimens A Serafin, A Cellini, CA Cavarretta, V Ruocco, F Angotzi, I Zatta, ... British Journal of Haematology, 2024 | | 2024 |
| P1075: ADVANCED-STAGE CHL INTERNATIONAL PROGNOSTICATION INDEX: EXTERNAL VALIDATION IN A SINGLE-CENTER RETROSPECTIVE PATIENT DATASET AND COMPARISON TO THE HASENCLEVER IPS A Cellini, CA Cavarretta, F Angotzi, V Ruocco, A Serafin, I Zatta, ... HemaSphere 7 (S3), e132523d, 2023 | | 2023 |
